Publications by authors named "Jerry Estep"

Background: Risk prognostication is essential to identify patients at risk of higher mortality following cardiac surgery.

Objectives: The Society for Cardiac Angiography and Intervention (SCAI) shock construct was adapted to cardiac surgical patients to create the CS-SCAI staging and it was applied at various time points and correlated with survival.

Methods: Retrospective analysis of Society of Thoracic Surgeons adult cardiac surgery database from January 2015 to December 2019.

View Article and Find Full Text PDF

Cardiac amyloidosis (CA), an infiltrative restrictive cardiomyopathy, is a frequently underrecognized etiology of diastolic heart failure (HF). This study aimed to evaluate inpatient outcomes among patients hospitalized with decompensated diastolic HF with and without a secondary diagnosis of amyloidosis, utilizing data from the National Inpatient Sample (2018-2021). Among 2,444,699 patients hospitalized for decompensated diastolic HF, 9205 (0.

View Article and Find Full Text PDF

Background: Left ventricular (LV) dilatation and extensive scar portend a poor prognosis in heart failure (HF). The Revivent TC system (BioVentrix Inc) is used either during a hybrid transcatheter-surgical or a surgical-only procedure to exclude transmural scar and reduce LV dimensions.

Objectives: The purpose of this study was to examine the safety and efficacy of the Revivent TC® anchor system in patients with HF.

View Article and Find Full Text PDF

Background: Effective and timely decongestion in acute heart failure (AHF) coupled with careful discharge planning is critical in the successful treatment of patients hospitalized for AHF. We leveraged an implementation science framework to develop a health system-wide diuretic management protocol (DMP) based on emerging clinical evidence.

Methods: We conducted stakeholder interviews using the Integrated Promoting Action on Research Implementation in Health Services (iPARiHS) Framework.

View Article and Find Full Text PDF
Article Synopsis
  • In patients with heart failure-related cardiogenic shock due to cardiac amyloidosis, using an intra-aortic balloon pump (IABP) may enhance hemodynamic stability and support their transition to advanced therapies like heart transplants.
  • A study reviewed 23 patients with cardiac amyloid who received IABP and found a 1-year survival rate of 74%, with 65% of them progressing to heart transplants.
  • The use of IABP notably increased mean arterial pressure and cardiac indices while decreasing various pressures related to heart function, indicating significant improvement in their cardiovascular status.
View Article and Find Full Text PDF
Article Synopsis
  • Heart failure (HF) is a growing health issue with increasing prevalence and mortality, requiring effective treatment strategies.
  • Current foundational therapies for HF include a mix of medications (like ARNIs and SGLTis) and device-based interventions (like ICDs and CRT), though significant risks remain even with treatment.
  • The focus is on enhancing care for HF patients through early diagnosis, personalized treatment plans, and continued research into optimizing the use of emerging device therapies alongside existing pharmacological options.
View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated a personalized treatment plan for heart failure patients, focusing on improving their medication regimen and overall health outcomes.
  • The results showed significant improvements in both medication scores and heart function, with many patients experiencing better symptoms and fewer hospitalizations.
  • The approach led to lower mortality rates compared to expected figures, suggesting that this aggressive protocol can effectively bridge the gap between existing medical knowledge and practical treatment for heart failure.
View Article and Find Full Text PDF

Cardiogenic shock is a multisystem pathology that carries a high mortality rate, and initial pharmacotherapies include the use of vasopressors and inotropes. These agents can increase myocardial oxygen consumption and decrease tissue perfusion that can oftentimes result in a state of refractory cardiogenic shock for which temporary mechanical circulatory support can be considered. Numerous support devices are available, each with its own hemodynamic blueprint.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates different heart failure (HF) types in patients diagnosed with transthyretin cardiac amyloidosis (ATTR-CA), revealing that a significant portion present with impaired systolic function, specifically heart failure with reduced ejection fraction (HFrEF) or mildly reduced ejection fraction (HFmrEF).
  • A retrospective analysis of patients from 2016 to 2022 found that 21.6% had HFrEF, 17.8% had HFmrEF, and 60.6% had heart failure with preserved ejection fraction (HFpEF), indicating a notable prevalence of systolic dysfunction in ATTR-CA cases.
  • The findings suggest that clinicians should maintain a high level of suspicion
View Article and Find Full Text PDF

Background: Patients have substantial variability in perioperative outcomes after left ventricular assist device (LVAD) implant. A perioperative multidimensional tool integrating mortality, adverse events (AEs), and patient-reported outcomes to assist in quality improvement initiatives is needed.

Methods: Patients undergoing HeartMate 3 LVAD implant (January 1, 2017 to January 31, 2024) in the Society of Thoracic Surgeons' Intermacs registry were studied.

View Article and Find Full Text PDF

Given the critical role of skeletal muscle in healthy aging, low muscle mass (myopenia) and quality (myosteatosis) can be used as predictors of poor functional and cardiometabolic outcomes. Myopenia is also a part of sarcopenia and malnutrition diagnostic criteria. However, there is limited evidence for using chest computed tomography (CT) to evaluate muscle health.

View Article and Find Full Text PDF
Article Synopsis
  • This study examines the risk factors for worsening renal function (wRF) in patients with transthyretin cardiac amyloidosis (ATTR-CA), which is linked to poor outcomes.
  • Out of 134 patients studied, 41.8% experienced wRF within the first year, with significant predictors being a higher New York Heart Association (NYHA) class, a lack of prior ischemic heart disease, and not being on SGLT-2 inhibitors.
  • The findings highlight that renal dysfunction is a common issue after ATTR-CA diagnosis, indicating that certain patient characteristics can help forecast who is at greater risk for developing wRF.
View Article and Find Full Text PDF

Background: Personalized risk (PR) estimates may enhance clinical decision making and risk communication by providing individualized estimates of patient outcomes. We explored stakeholder attitudes toward the utility, acceptability, usefulness and best-practices for integrating PR estimates into patient education and decision making about Left Ventricular Assist Device (LVAD).

Methods And Results: As part of a 5-year multi-institutional AHRQ project, we conducted 40 interviews with stakeholders (physicians, nurse coordinators, patients, and caregivers), analyzed using Thematic Content Analysis.

View Article and Find Full Text PDF

Previous studies suggest worse outcomes in patients with variant transthyretin cardiac amyloidosis (ATTR-CA) because of valine-to-isoleucine substitution at Position 122 (V122I) (ATTRv-CA) compared with patients with wild-type (WT) disease (ATTRwt-CA). Given V122I is almost exclusively found in Black patients, it is unclear if this is attributable to the biology of genotype or racial differences. Patients with ATTR-CA diagnosed between January 2001 and August 2021 were characterized into 3 categories: (1) White with ATTRwt-CA (White-WT); (2) Black with V122I ATTRv-CA (Black-V122I), and (3) Black with ATTRwt-CA (Black-WT).

View Article and Find Full Text PDF

Background: Sarcopenia and hypoalbuminemia have been identified as independent predictors of increased adverse outcomes, including mortality and readmissions, in hospitalized older adults with acute decompensated heart failure (ADHF). However, the impact of coexisting sarcopenia and hypoalbuminemia on morbidity and death in adults with ADHF has not yet been investigated. We aimed to investigate the combined effects of lower muscle mass (LMM) as a surrogate for sarcopenia and hypoalbuminemia on in-hospital and postdischarge outcomes of patients hospitalized for ADHF.

View Article and Find Full Text PDF

Heart failure (HF) is the leading cause of mortality in patients with acute myocardial infarction (AMI), with incidence ranging from 14% to 36% in patients admitted due to AMI. HF post-MI develops due to complex inter-play between macrovascular obstruction, microvascular dysfunction, myocardial stunning and remodeling, inflammation, and neuro-hormonal activation. Cardiogenic shock is an extreme presentation of HF post-MI and is associated with a high mortality.

View Article and Find Full Text PDF

Background: Transthyretin cardiac amyloidosis (ATTR-CM) is classically thought of as a progressive disease with preserved systolic function. The longitudinal clinical trajectories of ATTR-CM with impaired left ventricular ejection fraction (LVEF) remain unclear.

Methods: This is a single-center retrospective cohort study of consecutive patients with ATTR-CM who underwent two or more echocardiograms with baseline LVEF < 50%.

View Article and Find Full Text PDF

Background: The Minnesota Pectoralis Risk Score (MPRS) utilizes computed tomography-quantified thoracic muscle and clinical variables to predict survival after left ventricular assist device (LVAD) implantation. The model has not been prospectively tested in HeartMate 3 recipients.

Methods: A single-center HeartMate 3 cohort from July 2016 to July 2021 (n = 108) was utilized for this analysis.

View Article and Find Full Text PDF